News
KPTI
0.9705
+1.06%
0.0102
Weekly Report: what happened at KPTI last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at KPTI last week (0708-0712)?
Weekly Report · 07/15 09:05
Weekly Report: what happened at KPTI last week (0701-0705)?
Weekly Report · 07/08 09:06
Weekly Report: what happened at KPTI last week (0624-0628)?
Weekly Report · 07/01 09:06
Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 06/28 17:38
Karyopharm Therapeutics Price Target Cut to $7.00/Share From $8.00 by HC Wainwright & Co.
Dow Jones · 06/28 17:38
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $7
Benzinga · 06/28 17:28
KARYOPHARM THERAPEUTICS, INC. <KPTI.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $7 FROM $8
Reuters · 06/28 15:50
U.S. RESEARCH ROUNDUP-Alphabet, Equity Residential, Infinera
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Alphabet, Equity Residential, Infinera among companies with revised targets. Analysts cut their ratings on several companies, including Apple, Amazon and Facebook. Some analysts raised their target prices on other companies.
Reuters · 06/28 07:42
Weekly Report: what happened at KPTI last week (0617-0621)?
Weekly Report · 06/24 09:06
Weekly Report: what happened at KPTI last week (0610-0614)?
Weekly Report · 06/17 09:06
Karyopharm Therapeutics (KPTI) Receives a Buy from RBC Capital
TipRanks · 06/10 10:36
Weekly Report: what happened at KPTI last week (0603-0607)?
Weekly Report · 06/10 09:06
Hold Rating on Karyopharm Amid Competitive Landscape and Pending Data Outcomes
TipRanks · 06/04 08:06
Karyopharm Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 06/03 10:36
Paramount Global Shares Rise 6.6% on Revised Skydance Offer
Dow Jones · 06/03 10:27
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
Benzinga · 06/03 10:26
Buy Rating for Karyopharm on Strong Xpovio Clinical Data and Favorable Safety Profile
TipRanks · 06/03 10:16
Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)
TipRanks · 06/03 09:39
Weekly Report: what happened at KPTI last week (0527-0531)?
Weekly Report · 06/03 09:06
More
Webull provides a variety of real-time KPTI stock news. You can receive the latest news about Karyopharm Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.